Scientist grows new medication to treat type 2 diabetes without undesired reactions Kumar Jeetendra | June 24, 2020 Syracuse University science educator Dr. Robert P. Doyle has built up another medication lead to treat type 2 diabetes in a great many patients who are looking to all the more likely control their glucose without the basic symptoms of queasiness, spewing, and in select cases, undesired weight reduction. Doyle’s examination article, “Corrination of a …
New drug mixture improves blood glucose manipulate and weight reduction in mice Kumar Jeetendra | December 23, 2020 Scientists have demonstrated that adding an experimental cancer drug to a widely used diabetes treatment improves blood glucose control and weight loss in mice, according to a study published today in eLife. The results pave the way for clinical trials of this new drug combination as a more successful long-term remedy for countless individuals with …
FDA favors first conventional glucagon for injection to treat extreme hypoglycemia Kumar Jeetendra | December 29, 2020 Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packed in an emergency kit, for the treatment of severe hypoglycemia (very low blood sugar), which may occur in patients with diabetes mellitus. The drug is also indicated as a diagnostic aid in the radiologic examination of …
Study shows why children of obese moms have inclination to create metabolic illnesses Kumar Jeetendra | January 27, 2021 A Brazilian study published in the journal Molecular Human Reproduction helps understand why overweight mothers often have children with a propensity to develop metabolic disease during their lifetime, according to previous research. According to the authors,”transgenerational transmission of metabolic disorders” may be associated with Mfn2 deficiency in the mother’s oocytes (immature eggs). Mfn2 refers to …
FDA supports new medication for therapy of adults with chronic kidney infection Kumar Jeetendra | May 1, 2021 Today, the U.S. Food and Drug Administration accepted Farxiga (dapagliflozin) oral tablets to decrease the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression. Chronic kidney disease occurs when the kidneys are damaged and can’t filter blood …
